FBB
AZN icon

Fulton Breakefield Broenniman’s AstraZeneca AZN Stock Holding History

Fulton Breakefield Broenniman’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,324
Closed -$332K – 179
2020
Q4 		$332K Sell
3,324
-886
-21% -$93.8K 0.04% 114
2020
Q3 		$461K Hold
4,210
– – 0.05% 108
2020
Q2 		$445K Buy
+4,210
New +$435K 0.05% 114

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fulton Breakefield Broenniman's AZN Position: Q1 2021 in Review

Fulton Breakefield Broenniman sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 3,324 shares — an estimated $332K sold.

Fulton Breakefield Broenniman first reported a position in AZN in Q2 2020 and held it in 3 quarters. The position peaked at $461K in Q3 2020. 755 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

  • Fulton Breakefield Broenniman reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
  • Fulton Breakefield Broenniman sold 3,324 AstraZeneca shares in Q1 2021, an estimated $332K.
  • Fulton Breakefield Broenniman first reported a position in AstraZeneca in Q2 2020 and held it in 3 quarters.
  • Fulton Breakefield Broenniman's AstraZeneca position peaked at $461K in Q3 2020.
  • 755 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Fulton Breakefield Broenniman's 13F filing for Q1 2021, filed 9 Apr 2021.